|Dr. Wouter W. Latour M.B.A., M.D., MBA||Pres, CEO, CFO & Director||458.25k||N/A||1958|
|Dr. Sean N. Tucker||Founder & Chief Scientific Officer||327.61k||N/A||1968|
|Mr. John M. Harland M.B.A., CPA||Consultant||353.25k||N/A||1952|
|Ms. Margaret A. Echerd||VP, Corp. Controller & Principal Accounting Officer||N/A||N/A||1959|
|Mr. Brant Biehn||Sr. VP of Commercial Operations||N/A||N/A||N/A|
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Vaxart, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.